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Abstract  
 
A large number of neuroendocrine studies indicate a possible relationship between the 
Hypothalamo-Pituitary-Gonadal (HPG) axis and major depressive illness in men. This 
observation is not surprising, considering the similarities between the symptom profiles 
of depression and hypogonadism. However, owing to the strong likelihood that a number 
of other demographic, clinical and treatment covariates may potentially obscure a 
possible relationship between HPG and depression, studies in this area have produced 
somewhat inconsistent results. The main objective of the present study was to investigate 
the relationship between depression and HPG hormone levels in a population of 
hospitalised men. Another objective was to examine the relationship of a number of 
demographic, behavioural, clinical and treatment variables with HPG hormone levels and 
depression.   
METHOD: Serum hormones of the HPG axis (Luteinizing Hormone (LH), Follicle 
Stimulating Hormone (FSH), Free Testosterone (free T), Total Testosterone (total T) and 
Sex Hormone Binding Globulin (SHBG)) were compared between fifty-two male 
patients with Major Depressive Disorder (mean age = 42.04; SD = 14.1) and twenty-five 
male patients with other psychiatric conditions (mean age = 40.72; SD = 13.8) on 
admission into hospital. In addition, to elucidate the possible relationship between 
clinical outcome of depression and gonadal function, HPG parameters were measured in 
patients with depression 3 to 6 months following discharge. Based on their HDRS 
(Hamilton Depression Rating Scale) score, patients were categorised as remitters and 
non-remitters. Demographic, behavioral, clinical and treatment variables were also 
examined as possible correlates of hormone levels.  i
 RESULTS: Comparison between patients with depression and patients with other 
diagnoses indicated a significantly lower free T and total T in patients with depression. 
There were no differences in other hormone parameters between the two diagnostic 
groups. Correlational analyses indicated significant negative relationships between free T 
and total T and severity as well as duration of depression. Age was inversely correlated to 
both free T and total T, whereas BMI was negatively correlated with Total T and SHBG. 
There was a positive relationship between Total T as well as Free T and measures of 
sexual dysfunction. While no difference in hormone parameters was observed as a 
function of psychotic features, patients with melancholic features exhibited significantly 
lower levels of free T and total T compared to patients with no melancholic features. In 
the multiple regression analyses, age, duration and severity of depression were the 
strongest predictors of both free and total T. In separate regression analyses somatic 
features, over and above other features of depression were found to account most in the 
variability in free T and total T. Longitudinal analysis revealed significantly higher free T 
and total T levels on follow-up compared to baseline in the patients who remitted. There 
was no significant change in any of the hormones studies in the non-remitting group. 
CONCLUSION: The main findings of the present study support previous results that 
both total and free testosterone levels are lower during depression and that concentrations 
of free T and total T parallel changes in severity of depressive symptomatology. Further 
investigations into the mechanism for this observation, and perhaps examinations of 
testosterone supplementation for treatment of depression are in order. ii
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APPENDIX I 
 
 
Diagnostic Information 
 
 
 
Diagnosis 
 
Group 1 (n = 52) Group 2 (n = 25) 
Major Depressive Disorder 
 
52 0 
Schizophrenia 
 
0 13 
Generalised Anxiety Disorder 
 
0 6 
Panic Disorder 
 
0 6 
 
APPENDIX II 
 
 
Author’s contribution to the thesis’ research design and methodology 
 
 
 
Study design: The design of the study was performed in collaboration and under the 
guidance of the supervisor and co-supervisor. The author was solely responsible for 
researching and reviewing the literature, creating the study files and information 
collection papers.  
 
Recruitment and data collection: The author was responsible for recruitment of all of the 
patients, which included monitoring when prospective subjects were admitted and 
approaching patients, obtaining consent form as well as conducting interviews and 
gathering all necessary information.  
 
Blood collection: The author attended a one-week certified course on venipuncture which 
allowed her to gain experience and knowledge in venipuncture. The author had major 
involvement in blood collection: she performed almost all blood collections – there were 
few patients who it was difficult to collect blood from, in these cases blood collection 
was performed by a trained nurse employed by the clinic. The author performed 
centrifugation and pipetting. The author communicated directly with the pathology 
company regarding logistics and transport of blood samples and results.  
 
Statistical design and analysis:  The design, planning and execution of the statistical 
analysis were mainly performed by the author, under the supervision and guidance by the 
supervisor. The author was responsible for collecting data, data entry and management, 
application and interpretation of statistical analyses.   
 
 
 
 
 
 
APPENDIX III 
 
Medication Usage 
 
 
 Group 1 
(n = 52) 
Group 2 
(n = 25) 
  
SSRI  
  
 
20 (38.5 %) 
 
  6 (24.0 %) 
  
SNRI  
15 (28.9 %) 
 
  0 (0.0 %) 
  
Tricyclic   
 5 (9.6 %) 
   
  2 (8.0 %) 
  
Tetracyclic  
 
 
12 (23.1 %) 
   
  2 (8.0 %) 
  
RIMA 
 
   
0 (0.0 %) 
   
  1 (4.0 %) 
  
Mood stabilizers 
 
 
10 (19.2 %) 
   
  6 (24.0 %) 
  
Antipsychotics 
 
 
19 (36.5 %) 
 
12 (48.0 %) 
  
Antianxiety 
 
   
9 (17.3 %) 
   
  7 (28.0 %) 
  
 
 
